{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:37:41Z","timestamp":1789623461094,"version":"build-2803163510"},"reference-count":208,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtct.2026.05.005","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T22:26:38Z","timestamp":1778970398000},"page":"1055.e1-1055.e23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Expert Panel Review and Practical Guidance on Biomarker Testing with Engineered Immune Effector Cells"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1379-0876","authenticated-orcid":false,"given":"Viktoria","family":"Blumenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8005-3836","authenticated-orcid":false,"given":"Caroline","family":"Diorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5769-8409","authenticated-orcid":false,"given":"Jordan","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8932-863X","authenticated-orcid":false,"given":"Jennifer E.","family":"Agrusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1414-290X","authenticated-orcid":false,"given":"Alexandra","family":"Dreyzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4685-6499","authenticated-orcid":false,"given":"Gerulf","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7906-8782","authenticated-orcid":false,"given":"Manuel R.","family":"Espinoza-Gutarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9887-3464","authenticated-orcid":false,"given":"Marcus","family":"Geer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7445-3190","authenticated-orcid":false,"given":"Sneha","family":"Ramakrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saar","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-8032","authenticated-orcid":false,"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna V.","family":"Komanduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9574-5448","authenticated-orcid":false,"given":"Aude G.","family":"Chapuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5571-2775","authenticated-orcid":false,"given":"Sophie","family":"Paczesny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3905-0251","authenticated-orcid":false,"given":"Kai","family":"Rejeski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.jtct.2026.05.005_bib0001","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1200\/JCO-25-00399","article-title":"Lisocabtagene maraleucel versus standard of care for second-line relapsed\/refractory large B-cell lymphoma: 3-year follow-up from the randomized, Phase III TRANSFORM study","volume":"43","author":"Kamdar","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.005_bib0002","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.005_bib0003","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.005_bib0004","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.005_bib0005","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.005_bib0006","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jtct.2024.08.018","article-title":"Tocilizumab prophylaxis following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.005_bib0007","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41408-022-00741-2","article-title":"Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma","volume":"12","author":"Miller","year":"2022","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.005_bib0008","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.005_bib0009","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.jtct.2026.05.005_bib0010","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.jtct.2026.05.005_bib0011","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.005_bib0012","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1182\/blood.2024025910","article-title":"Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia","volume":"145","author":"Nair","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.005_bib0013","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03532-x","article-title":"An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma","author":"Raj","year":"2025","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.005_bib0014","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/bloodadvances.2024014455","article-title":"Development and validation of predictive models of early immune effector cell-associated hematotoxicity","volume":"9","author":"Liang","year":"2025","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.05.005_bib0015","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1182\/blood-2024-198499","article-title":"Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and\/or refractory multiple myeloma: preliminary results from the IMMagine-1 trial","volume":"144","author":"Freeman","year":"2024","journal-title":"Blood"},{"issue":"10450","key":"10.1016\/j.jtct.2026.05.005_bib0016","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0140-6736(24)00746-3","article-title":"CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study","volume":"404","author":"Frank","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2026.05.005_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1113882","article-title":"The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies","volume":"14","author":"Daei Sorkhabi","year":"2023","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.005_bib0018","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2013 a case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.005_bib0019","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/s41551-025-01492-8","article-title":"Fine tuning towards the next generation of engineered T cells","volume":"9","author":"Nguyen","year":"2025","journal-title":"Nat Biomed Eng"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.005_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010928","article-title":"Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols","volume":"13","author":"Cottrell","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.005_bib0021","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/bloodadvances.2021004604","article-title":"Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers","volume":"5","author":"Paczesny","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.005_bib0022","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/neuonc\/nox242","article-title":"The FDA NIH biomarkers, EndpointS, and other tools (BEST) resource in neuro-oncology","volume":"20","author":"Cagney","year":"2018","journal-title":"Neuro Oncol"},{"issue":"22","key":"10.1016\/j.jtct.2026.05.005_bib0023","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1158\/1078-0432.CCR-24-0830","article-title":"Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B-cell lymphoma","volume":"30","author":"Hubbeling","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.jtct.2026.05.005_bib0024","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.jtct.2026.05.005_bib0025","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood.2024024965","article-title":"Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes","volume":"145","author":"Freeman","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.005_bib0026","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41408-025-01338-1","article-title":"Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma","volume":"15","author":"Winkelmann","year":"2025","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.005_bib0027","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.005_bib0028","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.jtct.2026.05.005_bib0029","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1182\/blood.2023021620","article-title":"Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume","volume":"143","author":"Locke","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.005_bib0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-024-01540-x","article-title":"Conventional and novel [(18)F]FDG PET\/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma","volume":"17","author":"Leithner","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.005_bib0031","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/2643-3230.BCD-23-0056","article-title":"Baseline serum inflammatory proteins predict poor CAR T outcomes in diffuse large B-cell lymphoma","volume":"5","author":"Faramand","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"18","key":"10.1016\/j.jtct.2026.05.005_bib0032","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1158\/1078-0432.CCR-20-1434","article-title":"Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"26","author":"Faramand","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.jtct.2026.05.005_bib0033","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.05.005_bib0034","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified-EASIX predicts severe cytokine release syndrome and neurotoxicity after Chimeric Antigen Receptor (CAR) T cells","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"issue":"224","key":"10.1016\/j.jtct.2026.05.005_bib0035","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"19","key":"10.1016\/j.jtct.2026.05.005_bib0036","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.05.005_bib0037","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.2021015008","article-title":"Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma","volume":"140","author":"Jain","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.005_bib0038","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","article-title":"Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma","volume":"28","author":"Scholler","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.005_bib0039","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1158\/2643-3230.BCD-20-0227","article-title":"Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma","volume":"2","author":"van de Donk","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.005_bib0040","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jtct.2023.04.007","article-title":"Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma","volume":"29","author":"Rejeski","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.005_bib0041","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","article-title":"Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.005_bib0042","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13613-020-00697-1","article-title":"Role of albumin in the preservation of endothelial glycocalyx integrity and the microcirculation: a review","volume":"10","author":"Aldecoa","year":"2020","journal-title":"Ann Intensive Care"},{"issue":"5","key":"10.1016\/j.jtct.2026.05.005_bib0043","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/jth.15240","article-title":"Platelets maintain vascular barrier function in the absence of injury or inflammation","volume":"19","author":"Ho-Tin-No\u00e9","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.005_bib0044","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/blood-2017-06-742676","article-title":"Platelets and vascular integrity: how platelets prevent bleeding in inflammation","volume":"131","author":"Ho-Tin-No\u00e9","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.005_bib0045","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S2352-3026(17)30108-4","article-title":"EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis","volume":"4","author":"Luft","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2026.05.005_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.877477","article-title":"EASIX and severe endothelial complications after CD19-directed CAR-T cell therapy-a cohort study","volume":"13","author":"Korell","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.005_bib0047","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009220","article-title":"EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed\/refractory multiple myeloma","volume":"12","author":"Frenking","year":"2024","journal-title":"J ImmunoTher Cancer"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.005_bib0048","doi-asserted-by":"crossref","first-page":"e858","DOI":"10.1097\/HS9.0000000000000858","article-title":"Identifying early infections in the setting of CRS with routine and exploratory serum proteomics and the HT10 score following CD19 CAR-T for relapsed\/refractory B-NHL","volume":"7","author":"Rejeski","year":"2023","journal-title":"Hemasphere"},{"issue":"38","key":"10.1016\/j.jtct.2026.05.005_bib0049","doi-asserted-by":"crossref","first-page":"eadg3919","DOI":"10.1126\/sciadv.adg3919","article-title":"Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion","volume":"9","author":"Rejeski","year":"2023","journal-title":"Sci Adv"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.005_bib0050","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.005_bib0051","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.005_bib0052","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood.2025028833","article-title":"T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy","volume":"146","author":"Rejeski","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.005_bib0053","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/bloodadvances.2023011767","article-title":"Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality","volume":"8","author":"Rejeski","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2026.05.005_bib0054","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2026.05.005_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.01.888","article-title":"Prospective validation of CAR-HEMATOTOX and a simplified version predict survival in patients with large B-cell lymphoma treated with anti-CD19 CAR T-Cells: data from CART-SIE study","author":"Stella","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.005_bib0056","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/ajh.27056","article-title":"The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL","volume":"98","author":"Rejeski","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.005_bib0057","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.005_bib0058","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41408-022-00707-4","article-title":"Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma","volume":"12","author":"Alkhateeb","year":"2022","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.005_bib0059","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/jamaoncol.2023.7182","article-title":"Features and factors associated with myeloid neoplasms after chimeric antigen receptor T-cell therapy","volume":"10","author":"Gurney","year":"2024","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1016\/j.jtct.2026.05.005_bib0060","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","article-title":"Second primary malignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5,517 lymphoma and myeloma patients","volume":"30","author":"Tix","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.005_bib0061","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.005_bib0062","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/bloodadvances.2021005807","article-title":"Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma","volume":"6","author":"Kuhnl","year":"2022","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.005_bib0063","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","volume":"25","author":"Lin","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.005_bib0064","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.005_bib0065","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.005_bib0066","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41591-025-03532-x","article-title":"An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma","volume":"31","author":"Raj","year":"2025","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.jtct.2026.05.005_bib0067","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.005_bib0068","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/bloodadvances.2021006144","article-title":"Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment","volume":"6","author":"Schoeberl","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.005_bib0069","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1001\/jamaoncol.2022.3738","article-title":"Assessment of pretreatment and posttreatment evolution of neurofilament light chain levels in patients who develop immune effector cell\u2013associated neurotoxicity syndrome","volume":"8","author":"Butt","year":"2022","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.005_bib0070","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009525","article-title":"Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy","volume":"12","author":"Larue","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.005_bib0071","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1038\/s41591-025-03813-5","article-title":"Noncanonical and mortality-defining toxicities of CAR T cell therapy","volume":"31","author":"Rejeski","year":"2025","journal-title":"Nat Med"},{"issue":"30","key":"10.1016\/j.jtct.2026.05.005_bib0072","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1200\/JCO.23.02786","article-title":"Five-year follow-up of standard-of-care axicabtagene ciloleucel for large b-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"42","author":"Jain","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.005_bib0073","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70062","article-title":"Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed\/refractory B-cell lymphoma","volume":"9","author":"Stock","year":"2025","journal-title":"Hemasphere"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.005_bib0074","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/2643-3230.BCD-24-0163","article-title":"Dynamics of immune reconstitution and impact on outcomes across CAR-T cell products in large B-cell lymphoma","volume":"6","author":"Luan","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"16","key":"10.1016\/j.jtct.2026.05.005_bib0075","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jtct.2026.05.005_bib0076","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.005_bib0077","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.005_bib0078","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"9967","key":"10.1016\/j.jtct.2026.05.005_bib0079","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"355","key":"10.1016\/j.jtct.2026.05.005_bib0080","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor\u2013modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"21","key":"10.1016\/j.jtct.2026.05.005_bib0081","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.005_bib0082","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"177","key":"10.1016\/j.jtct.2026.05.005_bib0083","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.005_bib0084","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.005_bib0085","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.005_bib0086","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.005_bib0087","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.005_bib0088","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtct.2026.05.005_bib0089","first-page":"11","article-title":"Cytokines in CAR T cell-associated neurotoxicity","author":"Gust","year":"2020","journal-title":"Front Immunol"},{"issue":"16","key":"10.1016\/j.jtct.2026.05.005_bib0090","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.05.005_bib0091","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-22-0822","article-title":"Comprehensive serum proteome profiling of cytokine release syndrome and immune effector cell associated neurotoxicity syndrome in B-cell ALL patients receiving CART19","author":"Diorio","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.005_bib0092","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12859-024-05804-8","article-title":"PrCRS: a prediction model of severe CRS in CAR-T therapy based on transfer learning","volume":"25","author":"Wei","year":"2024","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jtct.2026.05.005_bib0093","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1450173","article-title":"Identification of early predictive biomarkers for severe cytokine release syndrome in pediatric patients with chimeric antigen receptor T-cell therapy","volume":"15","author":"Su","year":"2024","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.005_bib0094","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.005_bib0095","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.005_bib0096","first-page":"2998","article-title":"Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis","volume":"109","author":"Johnson","year":"2024","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.005_bib0097","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or deletion of IFN\u03b3 reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.005_bib0098","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.005_bib0099","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.005_bib0100","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.005_bib0101","article-title":"A major role for CD4(+) T cells in driving cytokine release syndrome during CAR T cell therapy","volume":"4","author":"Boulch","year":"2023","journal-title":"Cell Rep Med"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.005_bib0102","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1158\/2159-8290.CD-17-1368","article-title":"Chimeric antigen receptor t cell-mediated neurotoxicity in nonhuman primates","volume":"8","author":"Taraseviciute","year":"2018","journal-title":"Cancer Discov"},{"issue":"7735","key":"10.1016\/j.jtct.2026.05.005_bib0103","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-018-0774-y","article-title":"Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome","volume":"564","author":"Staedtke","year":"2018","journal-title":"Nature"},{"issue":"43","key":"10.1016\/j.jtct.2026.05.005_bib0104","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aax7969","article-title":"Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome","volume":"5","author":"Liu","year":"2020","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.005_bib0105","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1038\/s41467-023-38723-y","article-title":"Neutralizing IFNgamma improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies","volume":"14","author":"Manni","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2026.05.005_bib0106","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in aggressive non-Hodgkin lymphoma patients treated with CD19 CAR-T cells","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.005_bib0107","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2021.100168","article-title":"Proximity extension assay in combination with next-generation sequencing for high-throughput proteome-wide analysis","volume":"20","author":"Wik","year":"2021","journal-title":"Mol Cell Proteomics"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.005_bib0108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015004","article-title":"Aptamer-based multiplexed proteomic technology for biomarker discovery","volume":"5","author":"Gold","year":"2010","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.005_bib0109","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaci.2024.08.030","article-title":"Serum cytokine panels in pediatric clinical practice","volume":"155","author":"Gallo","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.005_bib0110","doi-asserted-by":"crossref","first-page":"838.e1","DOI":"10.1016\/j.jtct.2025.07.022","article-title":"Opportunities to improve antibiotic stewardship, and identification of blood biomarkers associated with bacteremia following CAR-T cell therapy","volume":"31","author":"Ng","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.005_bib0111","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ccell.2021.04.011","article-title":"Interleukin-1 in tumor progression, therapy, and prevention","volume":"39","author":"Garlanda","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtct.2026.05.005_bib0112","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/978-1-0716-3331-1_21","article-title":"Detection of free bioactive IL-18 and IL-18BP in inflammatory disorders","volume":"2691","author":"Fauteux-Daniel","year":"2023","journal-title":"Methods Mol Biol"},{"issue":"19","key":"10.1016\/j.jtct.2026.05.005_bib0113","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.005_bib0114","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s12079-018-0486-y","article-title":"Comprehensive network map of interferon gamma signaling","volume":"12","author":"Bhat","year":"2018","journal-title":"J Cell Commun Signal"},{"key":"10.1016\/j.jtct.2026.05.005_bib0115","article-title":"CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis","author":"Rocco","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.005_bib0116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2016.03.005","article-title":"Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and\/or siltuximab following CAR T cell therapy","volume":"434","author":"Chen","year":"2016","journal-title":"J Immunol Methods"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.005_bib0117","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cellimm.2012.01.001","article-title":"Aging is associated with circulating cytokine dysregulation","volume":"273","author":"\u00c1lvarez-Rodr\u00edguez","year":"2012","journal-title":"Cell Immunol"},{"issue":"2-3","key":"10.1016\/j.jtct.2026.05.005_bib0118","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12026-014-8491-6","article-title":"Effects of serum and plasma matrices on multiplex immunoassays","volume":"58","author":"Rosenberg-Hasson","year":"2014","journal-title":"Immunol Res"},{"key":"10.1016\/j.jtct.2026.05.005_bib0119","first-page":"13","article-title":"The cytokine network in acute myeloid leukemia","author":"Luciano","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.05.005_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/5530650","article-title":"Imbalance of chemokines and cytokines in the bone marrow microenvironment of children with B-cell acute lymphoblastic leukemia","volume":"2021","author":"Magalh\u00e3es-Gama","year":"2021","journal-title":"J Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.005_bib0121","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1016\/j.ymthe.2024.03.030","article-title":"Need for standardization of cytokine profiling in CAR T cell therapy","volume":"32","author":"Biery","year":"2024","journal-title":"Mol Ther"},{"issue":"24","key":"10.1016\/j.jtct.2026.05.005_bib0122","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2026.05.005_bib0123","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-22-0164","article-title":"Phenotypic composition of commercial anti-CD19 CAR-T cells affects in vivo expansion and disease response in large B-cell lymphoma patients","author":"Monfrini","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.005_bib0124","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cpt.2561","article-title":"In vivo cellular expansion of lisocabtagene maraleucel and association with efficacy and safety in relapsed\/refractory large B-cell lymphoma","volume":"112","author":"Ogasawara","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"10299","key":"10.1016\/j.jtct.2026.05.005_bib0125","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.005_bib0126","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/bloodadvances.2024012637","article-title":"CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity","volume":"8","author":"Hamilton","year":"2024","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.005_bib0127","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat Med"},{"issue":"10297","key":"10.1016\/j.jtct.2026.05.005_bib0128","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.jtct.2026.05.005_bib0129","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1182\/bloodadvances.2023010364","article-title":"Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R\/R DLBCL","volume":"7","author":"Blumenberg","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.005_bib0130","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/bloodadvances.2020004038","article-title":"Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse","volume":"5","author":"Faude","year":"2021","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.jtct.2026.05.005_bib0131","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1182\/bloodadvances.2023012470","article-title":"Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma","volume":"8","author":"Mejia Saldarriaga","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2026.05.005_bib0132","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.005_bib0133","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.jtct.2026.05.005_bib0134","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"8034","key":"10.1016\/j.jtct.2026.05.005_bib0135","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41586-024-07762-w","article-title":"Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission","volume":"634","author":"Bai","year":"2024","journal-title":"Nature"},{"issue":"7709","key":"10.1016\/j.jtct.2026.05.005_bib0136","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.005_bib0137","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1172\/JCI130144","article-title":"CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration","volume":"130","author":"Nobles","year":"2020","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.005_bib0138","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2020006770","article-title":"Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies","volume":"137","author":"Gauthier","year":"2021","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.jtct.2026.05.005_bib0139","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.005_bib0140","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.3324\/haematol.2023.284784","article-title":"Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series","volume":"109","author":"Scala","year":"2024","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.005_bib0141","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41591-025-03499-9","article-title":"Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody","volume":"31","author":"Braun","year":"2025","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.005_bib0142","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJMoa2309728","article-title":"CAR+ T-cell lymphoma after Cilta-cel therapy for relapsed or refractory myeloma","volume":"392","author":"Harrison","year":"2025","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jtct.2026.05.005_bib0143","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","article-title":"Indolent CD4+ CAR T-cell lymphoma after cilta-cel CAR T-cell therapy","volume":"390","author":"Ozdemirli","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.005_bib0144","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.005_bib0145","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/cyto.b.22165","article-title":"Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood","volume":"106","author":"Lee","year":"2024","journal-title":"Cytometry B Clin Cytom"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.005_bib0146","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057838","article-title":"Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials","volume":"8","author":"Jena","year":"2013","journal-title":"PLoS One"},{"issue":"22","key":"10.1016\/j.jtct.2026.05.005_bib0147","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1182\/bloodadvances.2023011399","article-title":"Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed\/refractory CLL","volume":"7","author":"Liang","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.005_bib0148","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12081641","article-title":"Evaluation of anti-CAR linker mAbs for CAR T monitoring after BiTEs\/bsAbs and CAR T-cell pretreatment","volume":"12","author":"Grahnert","year":"2024","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.005_bib0149","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013123","article-title":"Novel antibodies for identification, selection, and manipulation of T cells expressing Whitlow linker-containing CARs","volume":"13","author":"Kimble","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.005_bib0150","doi-asserted-by":"crossref","DOI":"10.3390\/cells10113208","article-title":"Sensitivity and specificity of CD19.CAR-T cell detection by flow cytometry and PCR","volume":"10","author":"Schanda","year":"2021","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.005_bib0151","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102820","article-title":"Assessment of CAR T cell frequencies in axicabtagene ciloleucel and tisagenlecleucel patients using duplex quantitative PCR","volume":"12","author":"Schubert","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.005_bib0152","doi-asserted-by":"crossref","first-page":"306.e1","DOI":"10.1016\/j.jtct.2023.12.672","article-title":"Digital PCR improves sensitivity and quantification in monitoring CAR-T cells in B cell lymphoma patients","volume":"30","author":"de la Iglesia-San Sebastian","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.jtct.2026.05.005_bib0153","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2022.5338","article-title":"Comparison of single copy gene\u2011based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19\u2011directed CAR T cells in treated patients","volume":"60","author":"Schubert","year":"2022","journal-title":"Int J Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.005_bib0154","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071970","article-title":"Accurate in-vivo quantification of CD19 CAR-T cells after treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) using digital PCR","volume":"12","author":"Badbaran","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtct.2026.05.005_bib0155","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.omtm.2019.12.018","article-title":"Digital PCR assays for precise quantification of CD19-CAR-T cells after treatment with Axicabtagene Ciloleucel","volume":"16","author":"Fehse","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"16","key":"10.1016\/j.jtct.2026.05.005_bib0156","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145459","article-title":"BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia","volume":"131","author":"Kong","year":"2021","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.jtct.2026.05.005_bib0157","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006596","article-title":"CAR T-cell detection scoping review: an essential biomarker in critical need of standardization","volume":"11","author":"Turicek","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.005_bib0158","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","author":"Fortuna","year":"2024","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.005_bib0159","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"14","key":"10.1016\/j.jtct.2026.05.005_bib0160","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood.2023021429","article-title":"Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity","volume":"142","author":"Graham","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.005_bib0161","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.005_bib0162","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"issue":"27","key":"10.1016\/j.jtct.2026.05.005_bib0163","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.005_bib0164","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41467-019-13880-1","article-title":"Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy","volume":"11","author":"Sheih","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2026.05.005_bib0165","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jha2.357","article-title":"Imagining the cell therapist: future CAR T cell monitoring and intervention strategies to improve patient outcomes","volume":"3","author":"Jain","year":"2022","journal-title":"EJHaem"},{"issue":"5","key":"10.1016\/j.jtct.2026.05.005_bib0166","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.2022015795","article-title":"CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR","volume":"140","author":"Shalabi","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.005_bib0167","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","article-title":"Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL","volume":"131","author":"Wood","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.005_bib0168","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2025.100588","article-title":"Minimal residual disease negative: a novel endpoint for accelerated approval; what providers should know","volume":"45","author":"Ranganathan","year":"2025","journal-title":"J Cancer Policy"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.005_bib0169","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pky069","article-title":"Validation of minimal residual disease as surrogate endpoint for event-free survival in childhood acute lymphoblastic leukemia","volume":"2","author":"Galimberti","year":"2018","journal-title":"JNCI Cancer Spectr"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.005_bib0170","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood"},{"issue":"224","key":"10.1016\/j.jtct.2026.05.005_bib0171","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.005_bib0172","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/2643-3230.BCD-23-0056","article-title":"Baseline serum inflammatory proteins predict poor CAR T outcomes in diffuse large B-cell lymphoma","volume":"5","author":"Faramand","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.005_bib0173","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/bloodadvances.2024014455","article-title":"Development and validation of predictive models of early immune effector cell-associated hematotoxicity","volume":"9","author":"Liang","year":"2025","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.jtct.2026.05.005_bib0174","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1182\/bloodadvances.2025016689","article-title":"Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections, and survival after CART in R\/R LBCL","volume":"9","author":"de Boer","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.05.005_bib0175","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"19","key":"10.1016\/j.jtct.2026.05.005_bib0176","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.jtct.2026.05.005_bib0177","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.jtct.2026.05.005_bib0178","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.jtct.2026.05.005_bib0179","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.005_bib0180","doi-asserted-by":"crossref","first-page":"9228","DOI":"10.1002\/cam4.5665","article-title":"Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T-cell therapy recipients","volume":"12","author":"Powell","year":"2023","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.005_bib0181","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000858","article-title":"Identifying early infections in the setting of CRS with routine and exploratory serum proteomics and the HT10 score following CD19 CAR-T for relapsed\/refractory B-NHL","volume":"7","author":"Rejeski","year":"2023","journal-title":"Hemasphere"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.005_bib0182","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2024.2381989","article-title":"Procalcitonin level threshold and antibiotic use in patients receiving chimeric antigen receptor T-cell therapy","volume":"29","author":"Ramesh","year":"2024","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.005_bib0183","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1186\/s12967-024-05308-2","article-title":"Rapid identification of early infections in febrile patients after CD19 target CAR-T cell therapy for B-cell malignancies","volume":"22","author":"Pu","year":"2024","journal-title":"J Transl Med"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.005_bib0184","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/bloodadvances.2021006144","article-title":"Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment","volume":"6","author":"Schoeberl","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.005_bib0185","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1001\/jamaoncol.2022.3738","article-title":"Assessment of pretreatment and posttreatment evolution of neurofilament light chain levels in patients who develop immune effector cell\u2013associated neurotoxicity syndrome","volume":"8","author":"Butt","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2026.05.005_bib0186","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/jitc-2024-009525","article-title":"Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy","volume":"12","author":"Larue","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.005_bib0187","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/ajh.27056","article-title":"The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL","volume":"98","author":"Rejeski","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.005_bib0188","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2026.05.005_bib0189","article-title":"Development of ALL-Hematotox (ALL-HT): predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia","author":"Nair","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.005_bib0190","doi-asserted-by":"crossref","unstructured":"Stella F, Pennisi M, Chiappella A, et al. Prospective validation of CAR-HEMATOTOX and a simplified version predict survival in patients with large B-cell lymphoma treated with Anti-CD19 CAR T-Cells: data from CART-SIE study. Transplantat Cellul Ther, Off Publicat Am Soc Transplantat Cellul Ther. doi:10.1016\/j.jtct.2025.01.888","DOI":"10.1016\/j.jtct.2025.01.888"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.005_bib0191","doi-asserted-by":"crossref","first-page":"283.e1","DOI":"10.1016\/j.jtct.2023.12.010","article-title":"Simple score of Albumin and CRP predicts high-grade toxicity in patients with multiple myeloma receiving CAR-T therapy","volume":"30","author":"Akhtar","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.005_bib0192","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1158\/2326-6066.CIR-22-0487","article-title":"Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy","volume":"11","author":"Rejeski","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtct.2026.05.005_bib0193","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified-EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor (CAR) T cells","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.jtct.2026.05.005_bib0194","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.05.005_bib0195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.877477","article-title":"EASIX and severe endothelial complications afTer CD19-directed CAR-T cell therapy-a cohort study","volume":"13","author":"Korell","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.005_bib0196","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009220","article-title":"EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed\/refractory multiple myeloma","volume":"12","author":"Frenking","year":"2024","journal-title":"J ImmunoTher Cancer"},{"key":"10.1016\/j.jtct.2026.05.005_bib0197","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03532-x","article-title":"An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma","author":"Raj","year":"2025","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.jtct.2026.05.005_bib0198","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1182\/bloodadvances.2023010712","article-title":"Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients","volume":"7","author":"Schuelke","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.005_bib0199","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2643-3230.BCD-21-0203","article-title":"Potential role of ifngamma inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy","volume":"3","author":"McNerney","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"19","key":"10.1016\/j.jtct.2026.05.005_bib0200","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.05.005_bib0201","article-title":"CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis","author":"Rocco","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.005_bib0202","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaci.2024.08.030","article-title":"Serum cytokine panels in pediatric clinical practice","volume":"155","author":"Gallo","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jtct.2026.05.005_bib0203","article-title":"Therapeutic Potential of TNFalpha and IL1beta Blockade for CRS\/ICANS in CAR-T Therapy via Ameliorating Endothelial Activation","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.005_bib0204","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/bloodadvances.2022006983","article-title":"Anakinra utilization in refractory pediatric CAR T-cell associated toxicities","volume":"6","author":"Diorio","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.005_bib0205","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.005_bib0206","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s40425-019-0767-x","article-title":"Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy","volume":"7","author":"Luo","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"20","key":"10.1016\/j.jtct.2026.05.005_bib0207","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1182\/bloodadvances.2020002592","article-title":"Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children","volume":"4","author":"Diorio","year":"2020","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.jtct.2026.05.005_bib0208","doi-asserted-by":"crossref","first-page":"6134","DOI":"10.1182\/bloodadvances.2023010708","article-title":"Free interleukin-18 is elevated in CD22 CAR T-cell-associated hemophagocytic lymphohistiocytosis-like toxicities","volume":"7","author":"Rocco","year":"2023","journal-title":"Blood Adv"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:00:34Z","timestamp":1788552034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726003489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":208,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666636726003489"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.005","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert Panel Review and Practical Guidance on Biomarker Testing with Engineered Immune Effector Cells","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}